Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02364362
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers
- First Posted Date
- 2015-02-11
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02361138
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2015-02-11
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT02361112
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Suspended
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 137
- Registration Number
- NCT02356991
- Locations
- 🇨🇳
Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China
🇨🇳Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China
The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT02356224
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02353975
The Drug-drug Interaction of SHR3824 and Metformin
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02354027
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02346175
A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT02336724
- Locations
- 🇨🇳
Nanjing Bayi Hospital, Nanjing, Jiangsu, China
Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 417
- Registration Number
- NCT02332512
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳Department of Medical Oncology, Cancer Center, Sun Yet-sen University, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath